1. Signaling Pathways
  2. Immunology/Inflammation
  3. PD-1/PD-L1

PD-1/PD-L1

Programmed death-1 (PD-1) is a receptor on T cells that has been shown to suppress activating signals from the T cell receptor when bound by either of its ligands, Programmed death-ligand 1 (PD-L1) or PD-L2. When PD-1 expressing T cells contact cells expressing its ligands, functional activities in response to antigenic stimuli, including proliferation, cytokine secretion, and cytotoxicity are reduced. PD-1/PD-Ligand interactions down regulate immune responses during resolution of an infection or tumor, or during the development of self tolerance.

Interference with the PD-1/PD-L1 interaction has also shown enhanced T cell activity in chronic infection systems. Chronic lymphocytic chorio meningitis virus infection of mice also exhibits improved virus clearance and restored immunity with blockade of PD-L1.

In addition to enhancing immunologic responses to chronic antigens, blockade of the PD-1/PD-L1 pathway has also been shown to enhance responses to vaccination, including therapeutic vaccination in the context of chronic infection.

PD-1/PD-L1 Related Products (21):

Cat. No. Product Name Effect Purity
  • HY-19745
    BMS-202 Inhibitor 98.45%
    BMS-202 is a potent PD-1/PD-L1 inhibitor, which binds to PD-1 and inhibits human PD-1/PD-L1 interaction, with an IC50 of 18 nM.
  • HY-P9904
    Atezolizumab Inhibitor 98.98%
    Atezolizumab is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.
  • HY-19991
    BMS-1 Inhibitor 99.61%
    BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM).
  • HY-P9903
    Nivolumab Inhibitor 98.56%
    Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody to treat advanced (metastatic) non-small cell lung cancer.
  • HY-100022
    Tomivosertib Inhibitor 99.49%
    Tomivosertib (eFT508) is a potent, highly selective, and orally bioavailable MNK1 and MNK2 inhibitor, with IC50s of 1-2 nM against both isoforms. Treatment of tumor cell lines with Tomivosertib (eFT508) leads to a dose-dependent reduction in eIF4E phosphorylation at serine 209 (IC50=2-16 nM). Tomivosertib (eFT508) also dramatically downregulates PD-L1 protein abundance.
  • HY-P9902
    Pembrolizumab Inhibitor 99.06%
    Pembrolizumab is a humanized antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.
  • HY-101093
    PD-1-IN-1 Inhibitor 99.63%
    PD-1-IN-1 is an inhibitor of programmed cell dealth-1 (PD-1) extracted from patent WO2015033299A1, compound example 4. PD-1-IN-1 can be used as immune modulator.
  • HY-108730
    Avelumab Inhibitor >99.0%
    Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.
  • HY-102011
    BMS-1166 Inhibitor 99.86%
    BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor with an IC50 of 1.4 nM. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation.
  • HY-P9919
    Durvalumab Inhibitor 99.50%
    Durvalumab (MEDI 4736) is an humanized anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.
  • HY-B0333
    Sulfamethizole Inhibitor 99.71%
    Sulfamethizole is a sulfathiazole antibacterial agent.
  • HY-101097
    PD-1-IN-17 Inhibitor
    PD-1-IN-17 is a programmed cell death-1 (PD-1) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nM.
  • HY-B1387
    Sulfamethoxypyridazine Inhibitor 99.01%
    Sulfamethoxypyridazine is a long-acting sulfonamide antibiotic, for treatment of Dermatitis herpetiformis.
  • HY-101098
    PD-1-IN-18 Inhibitor
    PD-1-IN-18 is a PD1 signaling pathway inhibitor, which acts as an immunomodulator.
  • HY-101097A
    PD-1-IN-17 (TFA) Inhibitor
    PD-1-IN-17 TFA is a programmed cell death-1 (PD-1) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nM.
  • HY-102011A
    BMS-1166 hydrochloride Inhibitor
    BMS-1166 hydrochloride is a potent PD-1/PD-L1 interaction inhibitor with an IC50 of 1.4 nM. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation.
  • HY-P1812A
    NP-12 (TFA) Antagonist
    NP-12 (TFA) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. NP-12 (TFA) exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs).
  • HY-128605
    PD-1-IN-22 Inhibitor
    PD-1-IN-22 is a potent programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction inhibitor with an IC50 of 92.3 nM.
  • HY-P1812
    NP-12 Antagonist
    NP-12 is a peptide antagonist of the PD-1 signaling pathway, which acts as an immunomodulatory agent for cancer therapy.
  • HY-101093B
    PD-1-IN-20 Inhibitor
    PD-1-IN-20 is the less active enantiomer of PD-1-IN-1. PD-1-IN-1 is an inhibitor of programmed cell dealth-1 (PD-1) extracted from patent WO 2015033299 A1, compound example 4.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.